Weinvestigated the changes in cellular components and neutrophil chemotactic factors in pleural fluid from 19 lung cancer patients who received intrapleural injection of OK-432 to treat malignant pleurisy. Not only neutrophil chemotactic activity (NCA) but also neutrophil count and percentage were increased significantly at 6 hours after OK-432injection. The neutrophil count was significantly correlated with NCAlevel. The levels of C5a and IL-8 in pleural fluid were increased significantly after OK-432 injection. The increased IL-8 level was associated with a increase of both NCAand neutrophil count. OK-432 treatment also induced a marked increase of IL-lfi and IL-6 in pleural fluid. Thus, intrapleural injection of OK-432 induced production of neutrophil chemotactic factors (IL-8 and C5a) and cytokines (IL-lfi and IL-6), which eventually attracted neutrophils into the pleural space. These observations suggest that neutrophil migration mediated by these factors and cytokines may contribute to the sclerosing effects of OK-432 treatment. (Internal Medicine 34: 352-356, 1995) 
Introduction
The pleura is often involved in the advanced stage of cancer, resulting in the development ofpleural effusion ( 1) . Biological response modifiers (BRM),anticancer agents, tetracyclines, and talc have been used to reduce the intrapleural accumulation of fluid (1) (2) (3) . Among these agents, the streptococcal preparation, OK-432, has been most commonlyused in Japan and is considered to be the most effective pleural sclerosing agent (4) .
OK-432exerts an antitumor effect in experimental animals and humans by stimulating host immunity (5) . Intraperitoneal or intrapleural administration of OK-432in patients with malignant effusion has been shown to recruit manyinflammatory cells, such as neutrophils, macrophages, and lymphocytes, to the site of effusion. Neutrophils are the first cells to migrate into the pleural or peritoneal cavity after the administration of OK-432 (6) . In an attempt to clarify the mechanismof neutrophil accumulation, we investigated the changes in cellular components and the levels of neutrophil chemotactic factors in the pleural fluid before and after the intrapleural injection of OK-432 in 19 patients with malignant pleurisy. We found that OK-432 induced an increase of neutrophil chemotactic factors leading to the migration of neutrophils into the pleural cavity.
Materials and Methods

Subjects
We studied 19 patients with lung cancer, including 12 men and 7 womenaged 40 to 77 years (median age: 66 years), all of whomhad cytology-proven malignant pleural effusions. The histological diagnosis was adenocarcinoma in 12 patients, small cell carcinoma in 5 patients, and squamous cell carcinoma in 2 patients. After thoracocentesis was performed, 500-1 ,000 ml of pleural fluid was aspirated. Then the patients received a single intrapleural injection of 5 Klinishe Einheit (KE) of OK-432 (Picibanil®, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan) in 50 ml of saline via the chest drainage tube. The chest tube was subsequently clampedfor two hours and the patients rested in various positions to ensure wide intrapleural distribution of OK-432.Then the chest tube was undampedand allowed to drain with continuous suction for a minimumof 48 hours. Pleural fluid was collected at 6, 24 and 48 hours after treatment by clamping the chest tube for two hours before each collection. 
Measurementof complementcomponents
The level of complementcomponentC5a in the pleural fluid was measured by radioimmunoassay (C5a des-Arg 125I Assay Kit, AmershamJapan, Tokyo, Japan). The cut-off value of the assay was set at 10 ng/ml according to the manufacturer's directions.
Measurementof cytokines
The level of interleukin-8 (IL-8) in pleural fluid and serum were measured by an ELISA(Quantikine HumanIL-8 Immunoassay Kit, R&DSystems, Minneapolis, MN). The interleurkin-1B (IL-1B) and interleukin-6 (IL-6) levels in pleural fluid were also measured by two different ELISAkits (IL-1B Immunoassay Kit, Medgenix Diagnostics, Fleurus, Belgium, and Predicta Interleukin-6 Kit, Genzyme, Cambridge, MA). Measurement of the serum IL-8 levels was performed in 10 lung cancer patients with pleural effusion and in 10 normal subjects.
Statistical analysis
Results were expressed as the mean± standard deviation (SD). Statistical analysis was done by employing the Student's t-test and corrrelation coefficients were determined by Pearson ' s method.
Results
Changes (p<0.01). In contrast, the absolute numberof MNCs in pleural fluid remained almost unchanged for up to 48 hours after OK-432 treatment.
Changes ofNCA
The NCAlevel in pleural fluid was increased significantly at 6 hours after OK-432treatment as compared to the pretreatment level (Fig. 1C) (p<0.05) , but returned to the pretreatment level at 24 and 48 hours after treatment. NCAshowed a significant correlation with the pleural fluid neutrophil count as demonstrated in Fig. 2A (r=0.86, p<0.001 ). In addition, the changes of NCAin the pleural fluid paralleled the changes of both the absolute neutrophil count and percentage. fluid samples from 10 lung cancer patients was 100-fold higher than that in their serum samples (1617 ± 1459 pg/ml vs 29.0 ± 24.1 pg/ml) (p<0.001). IL-8 was not detected in the serum obtained from 10 normal subjects. The IL-8 level in the pleural fluid was significantly increased at 6 hours after OK-432 treatment (p<0.01; Fig. 3A ). IL-8 levels after treatment were significantly correlated with both NCA (r=0.85, p<0.001) and the neutrophil count (r=0.93, p<0.001), as shown in Fig. 2B and 2C, respectively.
Changes of C5a Figure 3B shows the pleural fluid C5a levels before and 6 hours after OK-432 treatment. C5a was detected in 5 and 9 out of 12 patients before and after treatment, respectively. The mean C5a level increased from 6.8 ± 8.5 ng/ml to 62.1 ± 90. level at 6 hours affter treatment.
Changes oflL-lfi and IL-6 IL-IB was not detected in the pleural fluid before treatment. After the injection of OK-432, the mean IL-16 level was 252 ± 339 pg/ml, which was significantly higher than before treatment (p<0.01; Fig. 4A ). The pleural fluid IL-6 level also significantly increased, from 2.6 ± 2.3 ng/ml to 10.2 ± 2.7 ng/ ml, after OK-432 teratment (p<0.01; Fig. 4B ).
Discussion
The treatment of malignant pleural effusion is one of the major problems in the managementof patients with advanced cancer (1). Cell-mediated immunity is believed to play an important role in host defenses against cancer. Malignant pleural effusion is characterized by the accumulation of immune effector cells in the pleural space (5, 6) . Accordingly, a numberof agents that stimulate the immunesystem and may therefore induce pleural fibrosis have been used to treat malignant effusions. Although OK-432is considered to be the agent of choice for treatment of malignant pleurisy in Japan (4, 8) , its mechanismof action remains unclear. Intrapleural injection of OK-432is reported to enhance local cell-mediated immunity in lung cancer patients with pleural effusions (5) . In the present study, intrapleural injection of OK-432 significantly increased the number and percentage of neutrophils in the pleural fluid and the neutrophil count peaked 6 hours after OK-432 injection. The Boyden assay showed that NCAwas not associated with OK-432, suggesting that neutrophil accumulation in the pleural fluid was induced by chemotactic factors or factors generated in the pleural cavity which promoted migration of cells along a chemotactic gradient to the site of inflammation. In the present study, the NCAlevel was increased significantly at 6 hours after OK-432injection and the changes of NCAin the pleural fluid were correlated with changes in the absolute and relative neutrophil count. These observations suggest that neutrophil chemotactic factors mayhave been generated in the pleural fluid, causing the influx of neutrophils into the pleural space. Several chemotactic factors , such as complementfragments , bacteria-derived peptides, lipid mediators, and cytokines, have chemotactic activity for leukocytes, particularly neutrophils (9). Fujimura and Torisu previously reported that C5a, a complement-derived chemotactic factor, was responsible for the major part of the chemotactic activity generated in malignant peritoneal effusions after the injection of OK-432 (10) . In the present study, the pleural fluid levels of both C5a and IL-8 were increased after OK-432 injection. Moreover, changes of the pleural fluid IL-8 levels were correlated with changes of the neutrophil count and NCA. These findings indicate that in addition to C5a (1 1), IL-8 mediates neutrophil migration into the pleural space after OK-432injection. IL-8 is an inflammatory cytokine and a chemotactic factor for neutrophils that is produced by pleural macrophages and other nonimmunecells, such as endothelial cells, fibroblasts, tumor cells, and mesothelial cells (12 -14) . Itispresumedthatthe elevation ofIL-8 levels after OK-432treatment is due to the release from such cells, which are stimulated by either OK-432 or cytokines induced by OK-432 (12). IL-8 was already present in the pleural fluid before OK-432 injection and the IL-8 level was 100-fold higher than that in the serum of lung cancer patients with pleural effusion. The increased IL-8 levels in malignant pleural effusions may have resulted from production by mesothelial cells and tumor cells (13, 14) , but the relative contribution of each cell type is unknown at present. Several studies on neutrophil influx into the pleural space have shown that the major chemotactic factor for neutrophil depends onthetypeofinflammation (10, 1 1, 15-18) . Thus, both C5a and IL-8 may contribute to neutrophil influx into the pleural space after OK-432 injection.
Consistent with our results, the elevation of pleural fluid C5a and IL-8 levels is transient in models of pleurisy induced by sclerosing agents, and the levels of these chemotactic factors reach a peak at several hours after instillation (1 1, 17). Migration of neutrophils from the vascular compartmentto the site of inflammation is controlled by cell surface molecules on the migrating cells and on the endothelium (9). Cytokines like tumor necrosis factor (19), IL-1, and IL-6 induce the expression of selectins and ICAM-1 on the endothelium, allowing it to interact with migrating cells. Interactions with these molecules lead to neutrophil binding to the endothelium, and then neutrophil migration towards sites of inflammation is guided by chemotactic factors such as C5a and IL-8 (9) . Neutrophils induced by OK-432have antitumore activity and may destroy tumor cells in the pleural space (15, 20) . In addition, neutrophils release proteases and superoxide, which damage the pleural mesothelial cells and induce fibrosis (21, 22). Intrapleural injection of OK-432 induces marked fibrin production and this also promotes fibrosis (23).
In conclusion, intrapleural injection of OK-432increased the level of chemotactic factors (C5a and IL-8) and inflammatory cytokines (IL-1B and IL-6) in the pleural fluid, and also altered the predominant cellular component from MNCs to neutrophils. These changes promoted antitumor activity and pleural fibrosis.
